Enflonsia (clesrovimab-cfor)

No dosing information is available for this tab.

Administer clesrovimab-cfor as a single IM injection in the anterolateral aspect of the thigh; avoid gluteal region and areas near major nerve trunks/blood vessels.

Clesrovimab-cfor is available as 105 mg/0.7 mL in a single-dose prefilled syringe for IM injection; the solution is clear to slightly opalescent and colorless to slightly yellow.

Do not use the prefilled syringe if there is particulate matter, discoloration, damage, a broken security seal, or if expired or dropped.

Remove clesrovimab-cfor from the refrigerator and let the prefilled syringe sit at room temperature for about 15 minutes before injection.

To administer clesrovimab-cfor, hold the syringe barrel and twist the tip cap counterclockwise detaching the Luer Lock adaptor or finger flange extender. Attach a sterile Luer Lock needle by twisting clockwise until secure. Use a 22-25 gauge needle due to product viscosity.

If co-administered with vaccines, inject at a separate site with a separate syringe; do not mix with vaccines or medications in the same syringe/vial.

Keep refrigerated (2-8degreesC); protect from light in original carton. Can be stored at room temperature (20-25degreesC) for up to 48 hours and then used or discarded; do not freeze or shake.

No dosing information is available for this tab.

No dosing information is available for this tab.

Since clesrovimab-cfor is eliminated through catabolism, metabolic drug-drug interactions are not expected, although no formal interaction studies have been conducted.

There are no contraindication interactions for this drug.

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

Biologic Therapies/Anifrolumab

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Concurrent use of anifrolumab with other biologic therapies may result in additive or synergistic effects on the immune system.(1)

CLINICAL EFFECTS: Concurrent use of anifrolumab with other biologic therapies may increase the risk of serious infections.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The concurrent use of anifrolumab with other biologic therapies is not recommended.(1)

DISCUSSION: The combination of anifrolumab with other biologic therapies has not been studied and is not recommended.(1)

Igg Antibodies And Derivatives/Efgartigimod-Alfa

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3)

DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3)

Igg Antibodies And Derivatives/Nipocalimab-Aahu

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3)

DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3)

Moderate Interaction: Assess the risk to the patient and take action as needed.

Biologic Therapies/Belimumab

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Concurrent use of belimumab with other biologic therapies may result in additive or synergistic effects on the immune system.(1)

CLINICAL EFFECTS: Concurrent use of belimumab with other biologic therapies may increase the risk of serious infections.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The concurrent use of belimumab with other biologic therapies should be approached with caution.(1)

DISCUSSION: In a randomized, double-blind, placebo-controlled trial, more patients who received belimumab and rituximab experienced serious adverse events, serious infections, and post-injection systemic reactions (22.2%, 9%, and 13.2%, respectively) than patients who received belimumab with placebo (13.9%, 2.8%, 9.7%) or standard therapy (19.7%, 5.3%, 5.3%).(1) The combination of belimumab with other biologic therapies has not been studied and should be used cautiously.(1)

Igg Antibodies And Derivatives/Rozanolixizumab-Noli

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)

CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3)

DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3)

*Infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any of the components of clesrovimab.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

• No disease contraindications

The most frequently reported adverse reactions were injection-site erythema (3.8%), injection-site swelling (2.7%), and rash (2.3%).

There are no severe adverse reactions for this drug.

Less Frequent

• Injection site erythema
• Injection site sequelae
• Skin rash

No enhanced messaging available.

Safety and effectiveness of clesrovimab-cfor in preventing RSV lower respiratory tract disease have been demonstrated in neonates and infants during their first RSV season; safety and efficacy have not been established in children >12 months of age.

Clesrovimab-cfor is not indicated for use in females of childbearing potential.

Clesrovimab-cfor should not be used in females of childbearing potential.

No enhanced messaging available.